Combination therapy is more effective in improving the survival rate and reducing the risk of death. In advanced gastric cancer, CheckMate 649 reduced the risk of death by 20–35% in patients with programmed cell death ligand 1 (PD-L1) CPS ≥ 5. The gene discussed is CD274; the disease is gastric cancer.